- 1 SARS-CoV-2 RNA load in the lower respiratory tract, viral RNAemia and N-
- 2 antigenemia in critically ill adult COVID-19 patients: relationship with
- 3 biomarkers of disease severity
- 4 Beatriz Olea<sup>1</sup>, Eliseo Albert<sup>1</sup>, Ignacio Torres<sup>1</sup>, Roberto Gozalvo-Rovira<sup>2</sup>, Nieves
- 5 Carbonell<sup>3</sup>, José Ferreres<sup>3</sup>, Sandrine Poujois<sup>1</sup>, Rosa Costa<sup>1</sup>, Javier Colomina<sup>1</sup>, Jesús
- 6 Rodríguez<sup>2</sup>, María Luisa Blasco<sup>3</sup>, and David Navarro<sup>1,2\*</sup>
- <sup>1</sup>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,
- 8 Valencia, Spain.
- 9 <sup>2</sup>Department of Microbiology, School of Medicine, University of Valencia, Valencia,
- 10 Spain

19

24

- <sup>3</sup>Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research
- 12 Institute, Valencia, Spain.
- 14 \*Correspondence: David Navarro, Microbiology Service, Hospital Clínico
- 15 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
- 16 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010
- 17 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
- 18 david.navarro@uv.es.
- 20 **SUMMARY:** SARS-CoV-2 RNA load in the lower respiratory tract and plasma and N-
- 21 antigenemia followed different kinetics, correlated modestly with serum levels of
- 22 inflammatory and tissue-damage biomarkers and lymphopenia and did not appear to
- 23 increase overall mortality risk in critically ill adult COVID-19 patients.

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

**ABSTRACT** Background: Little is known about the comparative kinetics of SARS-CoV-RNA load in the lower respiratory tract and in blood compartment in patients admitted to the intensive care unit, and how these relate to biomarkers of COVID-19 severity. **Methods:** Seventy-three consecutive critically ill COVID-19 patients (median age, 65 years) were recruited. Serial lower respiratory tract (n=165) and plasma (n=340) specimens were collected. RT-PCR and lateral flow immunochromatography assay were used for SARS-CoV-2 RNA quantitation and N protein detection in plasma, respectively. Serum levels of inflammatory and tissue-damage biomarkers in paired specimens were analyzed. **Results:** SARS-CoV-RNA was detected in the lower respiratory tract of most patients (92%). Viral RNAemia and N-antigenemia were documented in 35.6% and 40.1% of patients, respectively. Viral RNAemia and N-antigenemia cleared at a faster rate than SARS-CoV-2 RNA in tracheal aspirates (TA). SARS-CoV-2 RNA load was higher (P<0.001) in TA than in plasma, and correlated significantly (Rho, 0.41; P<0.001). A modest correlation was found between SARS-CoV-2 RNA load in TA and plasma and levels of ferritin and lactose dehydrogenase (Rho≤0.3; P≤0.008) in paired serum specimens. Neither the dynamics of SARS-CoV-2 RNA load in TA and plasma, nor Nantigenemia detection rate differed between surviving and deceased patients. Yet, a trend towards a higher mortality was seen in patients with viral RNAemia (OR; 2.82; 95% CI, 0.94-8.47; *P*=0.06).

**Conclusion:** Neither SARS-CoV-2 replication rate in the lower respiratory tract nor its presence in the blood appeared to critically impact on survival in ICU COVID-19 patients. KEY WORDS: COVID-19, SARS-CoV-2 RNA load, SARS-CoV-2 RNAemia, SARS-CoV-2 N-antigenemia, lower respiratory tract, inflammation biomarkers. 

#### **INTRODUCTION**

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Severe COVID-19 is a multisystem disease involving the lower respiratory tract (LRT) and extra-pulmonary organs such as the liver, kidney, spleen and central nervous system [1]. Following infection, SARS-CoV-2 initially replicates in the upper respiratory tract (URT) before reaching the LRT [2,3], where it may cause severe damage, by virtue of its own cytopathogenicity and notably by inducing a persistent, dysregulated proinflammatory state [4,5]. While evidence has accumulated suggesting a direct relationship between SARS-CoV-2 RNA load in the URT early after infection and progression to severe clinical forms of COVID-19 [6-8], data linking the extent of virus replication in the LRT with clinical outcomes are scarce [9-11]. In this context, it remains to be elucidated whether acute respiratory distress syndrome and multiple organ failure, frequently ensuing in critically ill patients, are driven by uncontrolled viral replication in the LRT, dysregulated host-immune response, or both. SARS-CoV-2 may access the systemic compartment early after infection, as has been shown for SARS-CoV and MERS [12,13]. In fact, depending upon clinical severity, SARS-CoV-2 RNAemia can be detected in up to 88% of COVID-19 patients within the first week after symptoms onset [14-25], and has been associated with ICU admission, need for invasive mechanical ventilation, multiple organ failure and mortality rate [see metaanalysis in 26]. Likewise, SARS-CoV-2 nucleocapsid (N) antigenemia, which has also been found in a large percentage of COVID-19 patients [27,28], has been associated with higher ICU admission rates and overall mortality [27,29]. To our knowledge, no comprehensive analysis has been published concerning the interplay between the kinetics of SARS-CoV-2 RNA load in the LRT, viral RNAemia and N-antigenemia, and how these relate to the inflammatory state of patients with severe COVID-19. Studies of this nature may contribute in clarifying the pathogenesis of SARS-CoV-2

93 infection, as well as precisely identifying virological factors modulating COVID-19 94 prognosis. Here, we addressed these issues in a single-centre cohort of critically ill adult 95 COVID-19 patients. 96 PATIENTS AND METHODS 97 **Patients and specimens** 98 In this prospective observational study, 73 consecutive critically ill COVID-19 patients 99 (51 males and 22 females; median age, 65 years; range, 21 to 80 years) were recruited 100 during ICU stay between October 2020 and February 2021 (Table 1). Respiratory and plasma specimens were scheduled to be collected at least once a week from admission. 102 A total of 195 respiratory specimens (30 nasopharyngeal and 165 tracheal aspirates) and 103 340 plasma specimens were available for the analyses described below. Medical history 104 and laboratory data were prospectively recorded. The current study was approved by the 105 Ethics Committee of Hospital Clínico Universitario INCLIVA (May, 2020). 106 **Detection of SARS-CoV-2 RNA by RT-PCR** 107 Nasopharyngeal (NP) specimens were placed in 3 ml of Universal Transport Medium 108 (UTM, Becton Dickinson, Sparks, MD, USA). Tracheal aspirates (TA) from 109 mechanically ventilated patients were collected undiluted in sterile containers. 110 Specimens were kept at 4 °C until processed (within 6 hours of receipt). Plasma specimens were obtained by centrifugation of whole blood EDTA tubes, cryopreserved 112 at -80 °C and retrieved for analyses within one month after collection. Non-previously 113 thawed specimens were used for analyses. Nucleic acid extraction was performed using 114 a magnetic microparticle-based protocol (Abbott mSample Preparation SystemDNA) on 115 the Abbott m2000sp platform (Abbott Molecular (Des Plaines, IL, USA) with a starting

sample volume of 400 µl. SARS-CoV-2 RNA amplification was carried out by the

101

111

Abbott Real*Ti*me SARS-CoV-2 assay, a dual target reverse transcription polymerase chain reaction (RT-PCR) assay amplifying the RdRp and N-genes, on the m2000rt platform, following the manufacturer's instructions. The analytical sensitivity of the RT-PCR assay in TA and plasma specimens was assessed by spiking (in quintuplicate) 10-10<sup>4</sup> copies/ml of the AMPLIRUN® TOTAL SARS-CoV-2 RNA Control (Vircell SA, Granada, Spain) into RT-PCR negative TA or plasma samples. The limit of detection (LOD) was found to be approximately 100 copies/ml (95%) for both matrices (not shown), in agreement with previous estimates using NP [30,31]. SARS-CoV-2 viral loads are given in copies/ml throughout the study, as estimated using the abovementioned reference material. All specimens from a given patient were analysed in the same run in singlets.

### **Detection of SARS-CoV-2 N protein in plasma**

The CLINITEST® Rapid COVID-19 Antigen Test (Siemens, Healthineers, Erlangen, Germany), a lateral flow immunochromatography (LFIC) device licensed for detection of SARS-CoV-2 nucleocapsid protein NP or nasal swabs, was used on plasma specimens. The limit of detection (LOD) of the assay in plasma was determined by spiking a pre-pandemic plasma pool testing negative by RT-PCR with 10, 25, 50, 100 and 150 pg/ml of a recombinant N protein (MT-25C19NC, Certest Biotec S.L., Zaragoza, Spain). The LOD was found to be at least 50 pg/ml (Supplementary Fig. 1). Depleting experiments using a rabbit anti-N protein antibody (40143-R019; SinoBiological) confirmed the true nature of SARS-CoV-2 N detected in a number of discordant plasma specimens (testing negative by RT-PCR), as described in supplementary methods and shown in Supplementary Fig. 2.

#### **Laboratory measurements**

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

Clinical laboratory tests included serum levels of ferritin, D-Dimer (D-D), C reactive protein (CRP), interleukin-6 (IL-6), lactose dehydrogenase (LDH) and absolute lymphocyte counts. **Statistical methods** Frequency comparisons for categorical variables were carried out using Fisher's exact test. Differences between medians were compared using the Mann-Whitney U test. Spearman's rank test was used for analysis of correlation between continuous variables. Two-sided exact P values were reported. A P value <0.05 was considered statistically significant. The level of agreement between qualitative results provided by paired virological assays was assessed using Kappa-Cohen statistics. Logistic regression analyses were performed to assess risk factors for all-cause mortality. Parameters yielding P values <0.1 in univariate analyses were introduced in multivariate models. The analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). **RESULTS Patient clinical features** Patients were admitted to ICU at a median of 9 days (range, 2-25) after onset of symptoms. All patients presented with pneumonia and imaging findings compatible with COVID-19 on chest-x ray or CT-scan, and most eventually needed mechanical ventilation (87.7%). Median time of ICU stay was 18 days (range, 2–67). A total of 16 and 27 patients were under remdesivir and tocilizumab treatment, respectively, at ICU admission. Corticosteroids were given to 70 patients. A total of 29 patients died, at a median of 22 days (range, 7–66) after ICU admission. Kinetics of SARS-CoV-2 RNA load in the lower respiratory tract

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

Of the 64 patients undergoing mechanical ventilation, 61 had one or more TA collected (total number, 165; median of 2 specimens/patient; range, 1–11). The remaining three patients were not sampled. SARS-CoV-2 RNA was detected in 109 TA from 56 patients (91.8%). The remaining five patients tested negative for SARS-CoV-2 RNA in TA but had one or more positive NP collected prior to mechanical ventilation. SARS-CoV-2 RNA load in TA ranged between 3.03 and 10.6 log<sub>10</sub> copies/ml (median, 6.5 log<sub>10</sub> copies/ml). The dynamics of SARS-CoV-2 RNA load over time in TA is shown in Fig. 1A. Viral load remained relatively stable across the first two weeks from symptoms onset and began to decrease afterwards. No patient tested positive for SARS-CoV-2 RNA in TA beyond day 42. Neither remdesivir nor tocilizumab administration appeared to have a major impact on the dynamics of SARS-CoV-2 load in TA (Fig. 2, Supplementary Table 1). SARS-CoV-2 RNAemia and N-antigenemia A total of 340 plasma specimens from 73 patients (median, 4 samples/patient; range, 1-16) were available for analyses. SARS-CoV-2 RNAemia could be detected in 37 plasma specimens from 26 patients (35.6%). Median time to first detection of viral RNA in plasma was 10 days after symptoms onset (range, 3–32 days). The range of SARS-CoV-2 RNA loads measured in plasma was 1.69 to 5.27 log<sub>10</sub> copies/ml. Median SARS-CoV-2 RNA load was significantly lower in plasma (3.03 log<sub>10</sub> copies/ml) than in paired TA (Fig. 3A). A moderate yet significant correlation was found between SARS-CoV-2 RNA levels in TA and in paired plasma specimens (Fig. 3B). The dynamics of viral RNAemia are shown in Fig. 1B. SARS-CoV-2 RNAemia cleared at a faster rate than viral load in TA. In fact, viral RNAemia was not detected beyond day 32 after onset of

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

symptoms. A similar conclusion was drawn taking only paired TA and plasma specimens into consideration for the analyses (Supplementary Fig. 3). SARS-CoV-2 RNA load in TA was significantly higher (P<0.001) in presence than absence of concomitant viral RNAemia (median, 9.5 log<sub>10</sub> copies/ml; range, 4.3 to 10.4  $\log_{10}$  copies/ml vs. median, 6.2  $\log_{10}$  copies/ml; range, 3.0-10.6  $\log_{10}$  copies/ml). SARS-CoV-2 N-antigenemia was detected in 43 samples from 30 patients (41.0%). Median time to first N-antigenemia detection was 9 days after onset of symptoms (range, 3–29 days). No patient had N-antigenemia beyond day 32 after symptoms onset. The level of agreement between the qualitative results returned by plasma RT-PCR and N-antigenemia assay was moderate (k=0.57; P=<0.0001). As shown in Fig. 4A, a trend towards higher SARS-CoV-2 RNA loads was seen in plasma specimens testing positive for N-antigenemia assay than in those yielding negative results (P=0.083). In turn, SARS-CoV-2 RNA load in TA was significantly higher (P<0.001) in the presence of concomitant N-antigenemia than in its absence (Fig. 4B). Relationship between virological parameters, plasma levels of inflammatory or tissue-damage biomarkers and absolute lymphocyte counts Plasma levels of ferritin and LDH, but not IL-6, CRP, or D-D, were significantly higher when SARS-CoV-2 RNA was detected in paired TA or plasma specimens (Table 2), yet SARS-CoV-2 RNA loads in TA and plasma correlated moderately with plasma levels of ferritin and LDH (Fig. 5A and 5B, respectively). The degree of correlation between SARS-CoV-2 RNA load and serum levels biomarkers was similar when all respiratory specimens (including NP) were considered for the analyses (not shown). Plasma levels of all biomarkers except IL-6 were significantly higher in specimens testing positive for SARS-CoV-2 N antigen than in those returning negative results

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

(Table 2). Lymphocyte counts were significantly lower in the presence of SARS-CoV-2 RNA in TA and plasma or N antigen in plasma (Table 2). Nevertheless, the level of correlation (inverse) between SARS-CoV-2 RNA load in TA and plasma and lymphocyte counts was modest (Fig. 6). Virological parameters and mortality Dynamics of SARS-CoV-2 RNA load (initial, peak and trajectory) in TA following ICU admission were comparable across patients who either died or survived (Fig. 7 and Supplementary Fig. 4). Despite initial and peak SARS-CoV-2 RNA load in plasma being similar in surviving and deceased patients (P=0.11 and P=0.66, respectively; Supplementary Fig. 4), a trend towards a higher mortality rate (P=0.06) was noticed among patients exhibiting viral RNAemia (Table 3) in multivariate models adjusted for sex, age, comorbidities, APACHE II score and signs of organ failure. Occurrence of SARS-CoV-2 N-antigenemia was not associated with increased mortality (P=0.59). **DISCUSSION** Here, we conducted a comprehensive comparative analysis of the kinetics of SARS-CoV-2 RNA load in the lower respiratory tract and blood compartment in a cohort of adult COVID-19 patients admitted to ICU, of whom almost 90% underwent invasive ventilation. The potential relationship between SARS-CoV-2 load in these compartments and systemic inflammation status, absolute lymphocyte counts and mortality was also investigated. In our view, the data presented herein could have relevant pathogenetic implications, and the following findings are underlined. First, from a kinetics perspective, SARS-CoV-2 load in TA showed a descending trajectory from around two weeks after symptoms onset and was cleared in all survivors at seven weeks. Interestingly, neither remdesivir nor tocilizumab appeared to have a

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

major impact on these kinetics. This is in line with previous studies showing that neither drug had a tangible effect on SARS-CoV-2 RNA load in the upper airways, even when administered early after symptoms onset [33,34]. SARS-CoV-2 RNAemia and N-antigenemia followed comparable time courses to viral load in TA, but they cleared more rapidly. Detection of both viral RNAemia and Nantigenemia was more likely in patients exhibiting higher SARS-CoV-2 loads in TA. Moreover, SARS-CoV-2 RNA load was substantially higher in TA than in paired plasma, and a moderate correlation was found between SARS-CoV-2 RNA load in TA and in paired plasma specimens. Collectively, these data suggested that LRT may be a substantial source of SARS-CoV-2 RNA or N protein circulating in the peripheral blood compartment. Given that detection of SARS-CoV-2 RNA in blood has not been associated with infectious virus [19], we speculate that free RNA and soluble N protein, probably leaking from the LRT (and perhaps from other tissue sources), are the main biological forms of SARS-CoV-2 present in plasma. Second, SARS-CoV-2 RNAemia could be documented in one or more specimens from 35.6% of patients. This figure is substantially lower than was reported for ICU patients in other studies (77% in [14] and 88% in [18]). In these studies [14,18], however, a droplet-based digital PCR was used, which seemingly outperformed conventional RT-PCR assays such as the one used herein in terms of sensitivity. The above discrepancy could also be related to different timing of sample collection across studies, potentially important given the relatively rapid clearance of viral RNAemia documented in the current study. Third, SARS-CoV-2 N-antigenemia was detected in 41.0% of patients overall by means of LFIC, with an analytical sensitivity of around 50 pg/ml: those exhibiting higher

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

plasma viral RNA loads were more likely to test positive, as previously reported [28]. This concurs with the figure (49%) reported in a previous study [29] also using LFIC, but is much lower than the proportion found by Hingrat et al. [28] in a small subcohort of ICU patients (n=17), of whom most tested positive within the first two weeks after symptoms onset. Notably, an ultrasensitive immunoassay (limit of detection of 2.8 pg/ml) was employed in that study [28]. We did not measure serum antibodies against SARS-CoV-2, which may impact on the rate of N-antigenemia detection [29], and precludes certainty concerning the comparability of our data with those reported in the other studies [28,29]. Interestingly, in line with a previous report [28], N-antigenemia had a higher detection rate than viral RNAemia, which could be explained by the fact that N protein is likely less prone to degradation than RNA in cryopreserved-thawed specimens. Fourth, we provide some evidence linking the presence of detectable SARS-CoV-2 RNA in TA and plasma, as well as N-antigenemia, with increased levels of inflammation or tissue damage biomarkers (ferritin and LDH, respectively), and decreased abolute lymphocyte counts, although the correlation between levels of these biomarkers and viral loads in TA and plasma was modest at best. Previous studies reported a significant association between SARS-CoV-2 RNAemia detection and blood levels of IL-6 [21] or several cytokines and chemokines, such as IL-6, IL-10, C-reactive protein, ferritin, D-D and LDH [14]. In these studies, however, a single time point specimen per patient collected at ICU admission was considered for the analyses, as opposed to the serial specimens used herein. Unfortunately, serum IL-6 levels were not available in a large percentage of patients of the current cohort. Fifth, data from previous studies point to an association between protracted SARS-CoV-2 RNA clearance in LRT and/or simple presence of SARS-CoV-2 RNA in LRT

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

and increased risk of mortality [9,10,34]. In these studies, a wide variety of LRT specimens were used, including sputa, TA and bronchoalveolar lavage. No data proving a dose-dependent relationship between SARS-CoV-2 RNA load in LRT and mortality were provided. Herein, we found no differences between surviving and deceased patients in initial SARS-CoV-2 RNA load after ICU admission, viral peak load or overall dynamics of SARS-CoV-2 RNA load in TA. Sixth, both SARS-CoV-2 RNAemia and N-antigenemia have been independently associated with poor clinical outcome in mixed cohorts [see meta-analysis in 26] and in series including only ICU patients [14,29], in which patients who died displayed higher viral RNA loads in plasma collected at ICU admission than those who survived [14]. We found a trend towards an association between qualitative detection of SARS-CoV-2 RNA in plasma and mortality in multivariate logistic regression models, and failed to demonstrate higher initial or peak viral loads in deceased patients. We also found no evidence of an association between detection of N-antigenemia and mortality rate. Nevertheless, these data must be interpreted with caution due to the limited number of death events in our series. The main limitations of the current study are the relatively small sample size, the nonnegligible number of missing specimens, specially TA, compared with the planned sample collection schedule, and analytical methods which may have underestimated the viral RNAemia and N-antigenemia detection rate. Analysis of sequential specimens from patients could be considered a strength of the research. The current study contributes to filling a knowledge gap on the comparative dynamics of SARS-CoV-2 in LRT and in the systemic compartment in ICU patients, and provides further insight into the pathogenesis of SARS-CoV-2 infection in this patient subset. In

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

**AUTHOR CONTRIBUTIONS** 

this respect, whether poor clinical outcomes in critically ill patients are directly linked to the extent of virus replication in the LRT, to a dysregulated pro-inflammatory state (cytokine storm) [4,5], or both, remains to be elucidated. In our view, our data fit better with a pathogenetic model, in which SARS-CoV-2 replication in the LRT or its presence in the blood compartment at a certain point over the course of ICU stay might not be a major driver of systemic inflammation, lymphopenia, lung dysfunction, multisystemic organ failure and death. This does not invalidate the importance of virus replication rate in the URT in the early stage after infection in determining the clinical course of COVID-19 [6-8]. Further studies are needed to resolve this issue. **ACKNOWLEDGMENTS** No public or private funds were used for the current study. We are grateful to all personnel who work at Clinic University Hospital, in particular to those at Microbiology laboratory and the Intensive Care Unit for their commitment in the fight against COVID-19. Eliseo Albert holds a Juan Rodés Contract (JR20/00011) from the Health Institute Carlos III. Ignacio Torres holds a Río Hortega Contract (CM20/00090) the Health Institute Carlos III. We thank Siemens Healthineers (Erlangen, Germany) for providing reagents free of charge. FINANCIAL SUPPORT This work received no public or private funds. **CONFLICTS OF INTEREST** The authors declare no conflicts of interest.

- BA, EA, IT, RG-R, RC, JC and JR: Methodology and validation of data. NC, JF and
- 331 MLB: Medical care of ICU patients. DN: Conceptualization, supervision, writing the
- original draft. All authors reviewed the original draft.

## 333 **REFERENCES**

- 334 1. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med.
- **2020**;383:2451-2460.
- 336 2. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients
- infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020:
- retrospective cohort study. BMJ. **2020**;369:m1443
- 339 3. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-
- 340 CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and
- infectiousness: a systematic review and meta-analysis. Lancet Microbe. **2021**;2:e13-e22.
- 4. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. **2020**;383:2255-2273.
- 5. Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical
- 344 COVID-19: a rapid systematic review, meta-analysis, and comparison with other
- inflammatory syndromes. Lancet Respir Med. **2020**;8:1233-1244.
- 346 6. Alteri C, Cento V, Vecchi M, et al. Nasopharyngeal SARS-CoV-2 load at hospital
- admission as predictor of mortality. Clin Infect Dis. **2020** Jul 16:ciaa956.
- 348 7. Néant N, Lingas G, Le Hingrat Q, et al. Modeling SARS-CoV-2 viral kinetics and
- 349 association with mortality in hospitalized patients from the French COVID cohort. Proc
- 350 Natl Acad Sci U S A. **2021**;118:e2017962118.
- 351 8. Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-
- 352 19 mortality. Lancet Respir Med. **2020**;8:e70.

- 9. Buetti N, Wicky PH, Le Hingrat Q, et al. SARS-CoV-2 detection in the lower
- respiratory tract of invasively ventilated ARDS patients. Crit Care. **2020**; 24:610.
- 355 10. Huang Y, Chen S, Yang Z, et al. SARS-CoV-2 Viral Load in Clinical Samples from
- 356 Critically Ill Patients. Am J Respir Crit Care Med. 2020;201:1435-1438.
- 357 11. Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in
- 358 relation to COVID-19 severity. J Clin Invest. **2020**;130:5235-5244.
- 359 12. Grant PR, Garson JA, Tedder RS, Chan PK, Tam JS, Sung JJ. Detection of SARS
- 360 coronavirus in plasma by real-time RT-PCR. N Engl J Med. 2003;349:2468-2469.
- 361 13. Corman VM, Albarrak AM, Omrani AS, et al. Viral Shedding and Antibody
- 362 Response in 37 Patients with Middle East Respiratory Syndrome Coronavirus
- 363 Infection. Clin Infect Dis. **2016**;62:477-483.
- 364 14. Bermejo Martin JF, González Rivera M, Almansa R, et al. Viral RNA load in
- 365 plasma is associated with critical illness and a dysregulated host response in
- 366 COVID □ 19. Crit Care. **2020**; 24:691.
- 367 15. Berastegui □ Cabrera J, Salto □ Alejandre S, Valerio M, et al. SARS □ CoV □ 2
- 368 RNAemia is associated with severe chronic underlying diseases but not with
- 369 nasopharyngeal viral load. J Infect. **2020**:S0163 □ 4453:30719 □ 2.
- 370 16. Hogan CA, Stevens BA, Sahoo MK, et al. High frequency of SARS□CoV□2
- 371 RNAemia and association with severe disease. Clin Infect Dis. 2020:ciaa1054
- 372 17. Xu D, Zhou F, Sun W, et al. Relationship between serum SARS□CoV□2 nucleic
- acid (RNAemia) and organ damage in COVID 19 patients: a cohort study. Clin Infect
- 374 Dis. **2020**:ciaa1085.

- 375 18. Veyer D, Kernéis S, Poulet G, et al. Highly sensitive quantification of plasma severe
- acute respiratory syndrome coronavirus 2 RNA sheds light on its potential clinical
- value. Clin Infect Dis. Clin Infect Dis. **2020**:ciaa1196
- 378 19. Andersson MI, Arancibia ☐ Carcamo CV, Auckland K, et al. SARS ☐ CoV ☐ 2 RNA
- 379 detected in blood products from patients with COVID□19 is not associated with
- infectious virus. Wellcome Open Res. 2020; 5: 181.
- 381 20. Prebensen C, Myhre PL, Jonassen C, et al. SARS□CoV□2 RNA in plasma is
- associated with ICU admission and mortality in patients hospitalized with COVID□19.
- 383 Clin Infect Dis. **2020**:ciaa1338.
- 384 21. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS□CoV□2 viral load
- 385 (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL□6) level in
- critically ill COVID □ 19 patients. Clin Infect Dis. **2020**; 71: 1937 □ 1942.
- 387 22. Hagman K, Hedenstierna M, Gille □ Johnson P, et al. SARS □ CoV □ 2 RNA in serum
- as predictor of severe outcome in COVID□19: a retrospective cohort study. Clin Infect
- 389 Dis. **2020**:ciaa1285.
- 390 23. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
- 391 coronavirus in Wuhan, China. Lancet. **2020**; 395: 497 □ 506.
- 392 24. Chen W, Lan Y, Yuan X, et al. Detectable 2019 □nCoV viral RNA in blood is a
- 393 strong indicator for the further clinical severity. Emerg Microbes Infect. 2020; 9: 469 □
- 394 473.
- 395 25. Eberhardt KA, Meyer Schwickerath C, Heger E, et al. RNAemia corresponds to
- 396 disease severity and antibody response in hospitalized COVID□19 patients. Viruses.
- **2020**; 12: 1045.

- 398 26. Tang K, Wu L, Luo Y, Gong B. Quantitative assessment of SARS-CoV-2 RNAemia
- and outcome in patients with coronavirus disease 2019. J Med Virol. **2021** Feb 16. doi:
- 400 10.1002/jmv.26876
- 401 27. Ogata AF, Maley AM, Wu C, et al. Ultrasensitive serial profiling of SARS-CoV-2
- 402 antigens and antibodies in plasma to understand disease progression in COVID-19
- patients with severe disease. Clin Chem. **2020**;66:1562e72
- 404 28. Hingrat QL, Visseaux B, Laouenan C, et al. Detection of SARS-CoV-2 N-antigen in
- 405 blood during acute COVID-19 provides a sensitive new marker and new testing
- 406 alternatives. Clin Microbiol Infect. **2020**:S1198-743X(20)30721-7.
- 407 29. Martin-Vicente M, Almansa R, Martínez I, et al. Absent or insufficient anti-SARS-
- 408 CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma,
- 409 antigenemia and mortality in COVID-19 patients. medRxiv 2021
- 410 https://doi.org/10.1101/2021.03.08.21253121
- 411 30. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC.
- 412 Comparison of the analytical sensitivity of seven commonly used commercial SARS-
- 413 CoV-2 automated molecular assays. J Clin Virol. **2020**;130:104578.
- 414 31. Degli-Angeli E, Dragavon J, Huang ML, et al. Validation and verification of the
- 415 Abbott RealTime SARS-CoV-2 assay analytical and clinical performance. J Clin Virol.
- 416 **2020**;129:104474.
- 417 32. Goldberg E, Ben Zvi H, Sheena L, et al. A real-life setting evaluation of the effect of
- 418 remdesivir on viral load in COVID-19 patients admitted to a large tertiary center in
- 419 Israel. Clin Microbiol Infect. **202**1:S1198-743X(21)00113-0

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

33. Masiá M, Fernández-González M, Padilla S, et al. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study. EBioMedicine. 2020;60:10299 34. Bitker L, Dhelft F, Chauvelot L, et al. Protracted viral shedding and viral load are associated with ICU mortality in Covid-19 patients with acute respiratory failure. Ann Intensive Care. 2020;10:167. FIGURE LEGENDS **Figure 1.** Kinetics of SARS-CoV-RNA load in the lower respiratory tract (tracheal aspirates) (A) and plasma (B) of critically ill patients undergoing invasive ventilation. **Figure 2.** Effect of remdesivir or tocilizumab treatment on the kinetics of SARS-CoV-2 RNA load in the lower respiratory tract (tracheal aspirates) in critically ill patients undergoing invasive ventilation. Panels A and C depict the kinetics of SARS-CoV-2 RNA load in patients receiving remdesivir (A) or tocilizumab (C). The arrow indicates the time of treatment initiation. Remdesivir was administered to 16 patients at a median of 7 days (range, 2–13) since symptoms onset, for a median of 4 days (range, 1–5). Tocilizumab was prescribed to 27 patients (a single dose in 24 patients and two doses in the remaining three patients) at a median of 9 days (range, 3-28) since the onset of symptoms. Panels B and D depict SARS-CoV-2 RNA load kinetics in patients not treated with remdesivir (B) or tocilizumab (D). Figure 3. SARS-CoV-2 in the lower respiratory tract (tracheal aspirates) and plasma in critically ill patients undergoing invasive ventilation. Panel A shows SARS-CoV-2 RNA load in both compartments. Panel B shows the level of correlation between

443 SARS-CoV-2 RNA load in tracheal aspirates and plasma specimens. P values and 444 Spearman Rho value are shown. 445 Figure 4. SARS-CoV-2 RNA load in plasma (A) and lower respiratory tract, i.e., 446 tracheal aspirates (B) in critically ill patients undergoing invasive ventilation, in the 447 presence or absence of SARS-CoV-2 N protein in paired plasma specimens. P values 448 for comparisons are shown. 449 Figure 5. Correlation of serum levels of ferritin (A, C) and lactose dehydrogenase 450 (LDH: B, D) with SARS-CoV-2 RNA load in paired lower respiratory tract specimens 451 (tracheal aspirates) and plasma specimens from critically ill patients undergoing 452 invasive ventilation. Spearman Rho and P values are shown. 453 **Figure 6.** Correlation between SARS-CoV-2 RNA load in lower respiratory tract (upper 454 panel) and plasma (lower panel) and absolute lymphocyte counts in paired specimens. 455 Spearman Rho and P values are shown. 456 Figure 7. Kinetics of SARS-CoV-2 RNA load in the lower respiratory tract (tracheal 457 aspirates) in critically ill patients undergoing invasive ventilation who either died or 458 survived. P values for comparisons are shown. 459 **Supplementary Figure 1.** Evaluation of the limit of detection of the 460 CLINITEST® Rapid COVID-19 Antigen Test (Siemens Healthineers, Erlangen, 461 Germany) for detection of SARS-CoV-2 N protein in plasma specimens. A pre-462 pandemic plasma pool testing negative by RT-PCR was spiked with 10, 25, 50, 100 and 463 150 pg/ml of a recombinant N protein (MT-25C19NC, Certest Biotec S.L., Zaragoza, 464 Spain). 465 Supplementary Figure 2. Representative example of a depleting experiment

demonstrating the true nature of SARS-CoV-2 N protein detected in plasma specimens

with N-antigenemia and testing negative for SARS-CoV-2 RNA by RT-PCR. A rabbit anti-N protein antibody (40143-R019; SinoBiological) was used for N protein depletion. An isotype-matched rabbit antibody was employed as a control.

Supplementary Figure 3. SARS-CoV-2 RNA load in plasma (A) and paired respiratory tract specimens (tracheal aspirates and nasopharyngeal exudates) (B) in critically ill patients undergoing invasive ventilation in the presence or absence of SARS-CoV-2 N protein in paired plasma specimens. *P* values for comparisons are shown.

Supplementary Figure 4. SARS-CoV-2 RNA peak load in plasma (upper panel) and tracheal aspirates (lower panel) in ICU patients who died or survived. *P* values for comparisons are shown.

Table 1. Baseline clinical characteristics of population at Intensive Care Unit admission	f the study				
Variable	no. (%)				
Gender					
Male	51 (69.9)				
Female	22 (30.1)				
Acute physiology and chronic health evaluation (APACHE)					
II score					
<10	14 (19.2)				
10-14	27 (37.0)				
15-29	32 (43.8)				
Comorbidities					
Diabetes mellitus	18 (24.7)				
Asthma/ Chronic lung disease	11 (15.0)				
Hypertension	33 (45.2)				
Obesity	38 (52.0)				
Chronic heart disease	9 (12.3)				
Vascular disease	7 (9.6)				
Cancer	3 (4.1)				
Hematologic disease	3 (4.1)				
Number of comorbidity conditions					
One	22 (30.1)				
Two or more	33 (45.2)				
None	18 (24.7)				
Oxygenation and ventilator support	,				
Invasive mechanical ventilation	64 (87.7)				
PiO2/FiO2 <150 mmHg	58 (79.5)				
Acute kidney disfunction	17 (23.3)				
Antiviral or anti-inflammatory treatment					
Remdesivir	16 (21.9)				
Corticosteroids	70 (95.9)				
Tocilizumab	27 (36.9)				


Table 2. Qualitative detection of SARS-CoV-2 RNA in the lower respiratory tract or plasma or SARS-CoV-2 N protein in plasma and blood levels of biomarkers of COVID-19 severity.

Parameter Median (range)	Qualitativ e result of a given virological parameter	no. of paired specimens	SARS-CoV-2 RNA load in tracheal aspirates	P value	no. of paired specimens	SARS-CoV-2 RNAemia	P value	no. of paired specimens	SARS-CoV-2 N- antigenemia	P value
IL-6 in	Pos	23	111.4 (4-3,548)	0.84	9	111.4 (10.8-1363.)	0.92	14	105.8 (4-3,548)	0.69
pg/ml.	Neg	2	142 (22-262)	0.64	40	141.8 (4-3,548)		35	148.6 (4.7-3,437)	
Ferritin in	Pos	82	805.5 (69-6,440)	0.01	31	1,176 (147-6,440)	< 0.001	34	971.5 (147-6,440)	0.03
ng/ml.	Neg	34	421.5 (46-2,659)	0.01	211	590 (42-5,847)	<0.001	208	599 (42-5,847)	
D-D in ng/ml.	Pos	101	1,730 (270- 29,940)	0.87	36	1,535 (320-9,170)	0.17	41	1,350 (320-18,870)	0.03
	Neg	49	1,790 (270- 16,160)		274	1740 (270-60,000)		269	1,760 (270-60,000)	
LDH in UI/l.	Pos	105	687 (93-2,132)	0.001	36	765.5 (329-1,720)	0.002	43	748 (214-1,720)	0.002
LDH III UI/I.	Neg	51	520 (214-1,395)		281	637 (58-2,132)	0.002	274	632.5 (58-2,132)	
CRP in mg/l.	Pos	107	35 (1-746)	0.62	36	47.95 (1.2-459)	0.38	42	61.55 (1-459)	0.01
<i>8</i>	Neg	54	32.85 (1-606.7)		299	30.7 (1-746)		293	29.9 (1-746)	
Lymphocytes	Pos	74	0.96 (0.02-3.73)	<0.001	26	0.72 (0.02-3.13)	<0.001	27	0.83 (0.02-1.65)	0.001
in cell/μl	Neg	42	1.40 (0.44-2.43)	<0.001	209	1.13 (0.17-3.73)	<0.001	208	1.12 (0.17-3.73)	


CRP, C-reactive protein; D-D, Dimer-D; IL-6, interleukin-6; LDH, lactose dehydrogenase.


	Univariate		Multivariate		
Variable	OR (CI, 95%)	P	OR (95% CI)	D1	
		value	,	P value	
Sex	+	1	+	1	
Males vs. females	1.63 (0.56-4.66)	0.36	-		
Age		1			
≥65 vs. < 65 years	1.78 (0.69-4.58)	0.23	-		
Comorbidities (Yes vs. no)	1.44 (0.47-4.39)	0.52	-		
Obesity	0.78 (0.30-1.99)	0.60	-		
Diabetes mellitus	2.37 (0.80-6.99)	0.11	-		
Hypertension	1.55 (0.60-3.98)	0.36	-		
Asthma/Chronic lung disease	2.03 (0.56-7.42)	0.28			
Chronic heart disease	3.56(0.81-15.6)	0.09	1.79 (0.33-9.68)	0.49	
Vascular disease	1.15 (0.24-5.58)	0.85			
<b>Acute Physiology And Chron</b>	ic Health Evaluat	ion II			
Increase by one unit	1.1 (0.98-1.22)	0.09	1.03 (0.91-1.16)	0.66	
<10 (ref)					
10-14	1.72 (0.43-6.91)	0.44			
15-29	1.94 (0.50-7.53)	0.33			
≤15 vs >15	2.17 (0.81-5.82)	0.12			
Organ failure	, , ,			1	
Peak serum creatinine levels	3.87 (1.23-	0.02	2.04 (0.54-7.67)	0.29	
≥1.3 vs. <1.3	12.12)		,		
$PiO_2/FiO_2 < 150 \text{ vs.} \ge 150 \text{ at}$	0.583 (0.19-	0.34			
admission	1.78)				
Requirement of vasoactive	5.93 (2.12-16.6)	0.001	6.34 (2.17-18.5)	0.001	
medication within 24 h after	,		,		
ICU admission					
Mechanical ventilation within	2.34(0.67-8.15)	0.18			
48 h of ICU admission	,				
Antiviral or anti-inflammato	rv treatments	1			
Tocilizumab (Yes vs. No)	1.36 ( 0.52-	0.52			
, , , , , , , , , , , , , , , , , , , ,	3.59)				
Remdesivir (Yes vs. No)	0.71 (0.21-2.34)	0.57			
Virological parameters	011 = (012 = 10 1)				
Increase by two units of	1.39 (0.78-2.48)	0.26			
SARS-CoV-2 RNA load	1.05 (0170 2110)	0.20			
(log10 copies/mL)					
Initial SARS-CoV-2 RNA	0.81 (0.29-2.24)	0.68			
load in tracheal aspirates	0.01 (0.2) 2.21)	0.00			
$>7.1 \text{ vs.} \le 7.1 \log 10 \text{ copies/ml}$					
Initial SARS-CoV-2 RNA	1.68 (0.52-5.43)	0.38			
load in plasma (>3.0 vs. $\leq$ 3.0	1.00 (0.02 0.10)	0.50			
log <sub>10</sub> copies/ml)					
SARS-CoV-2 RNA peak load	0.63 (0.22-1.83)	0.39			
in tracheal aspirates ( $\geq 7.5$ vs.	0.03 (0.22-1.03)	0.37			
	I	1	i		


SARS-CoV-2 RNA peak load	0.53 (0.11-2.55)	0.43				
in plasma (>5.6 vs. $\leq$ 5.6 log <sub>10</sub>						
copies/ml)						
SARS-CoV-2 N-antigenemia	1.29 (0.49-3.34)	0.59				
(Yes vs. No)						
SARS-CoV-2 RNAemia (Yes	2.49 (0.93-6.66)	0.07	2.82 (0.94-8.47)	0.06		
vs. No)						
ICU, intensive care unit; OR, Odds ratio.						



Follow-up (days after symtoms onset)







В

D

Follow-up (days after symtoms onset)

